These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21048707)

  • 1. Microdose study of 14C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of parent drug and metabolites in healthy subjects.
    Tozuka Z; Kusuhara H; Nozawa K; Hamabe Y; Ikushima I; Ikeda T; Sugiyama Y
    Clin Pharmacol Ther; 2010 Dec; 88(6):824-30. PubMed ID: 21048707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Brian Houston J; Oosterhuis B; Bjerrum OJ; Grynkiewicz G; Alder J; Rowland M; Garner C
    Eur J Pharm Sci; 2011 Jun; 43(3):141-50. PubMed ID: 21540108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
    Lappin G; Kuhnz W; Jochemsen R; Kneer J; Chaudhary A; Oosterhuis B; Drijfhout WJ; Rowland M; Garner RC
    Clin Pharmacol Ther; 2006 Sep; 80(3):203-15. PubMed ID: 16952487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdose pharmacogenetic study of ¹⁴C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9∗3 on its pharmacokinetics and metabolism.
    Ikeda T; Aoyama S; Tozuka Z; Nozawa K; Hamabe Y; Matsui T; Kainuma M; Hasegawa S; Maeda K; Sugiyama Y
    Eur J Pharm Sci; 2013 Jul; 49(4):642-8. PubMed ID: 23727057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept.
    Mooij MG; van Duijn E; Knibbe CA; Windhorst AD; Hendrikse NH; Vaes WH; Spaans E; Fabriek BO; Sandman H; Grossouw D; Hanff LM; Janssen PJ; Koch BC; Tibboel D; de Wildt SN
    Clin Pharmacokinet; 2014 Nov; 53(11):1045-51. PubMed ID: 25227283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerator mass spectrometry analysis of background (14)C-concentrations in human blood: aiming at reference data for further microdosing studies.
    Minamimoto R; Hamabe Y; Miyaoka T; Hara T; Yoshida K; Oka T; Inoue T
    Ann Nucl Med; 2008 Dec; 22(10):883-9. PubMed ID: 19142707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Use of [
    Mooij MG; van Duijn E; Knibbe CAJ; Allegaert K; Windhorst AD; van Rosmalen J; Hendrikse NH; Tibboel D; Vaes WHJ; de Wildt SN
    Clin Pharmacokinet; 2017 Oct; 56(10):1185-1195. PubMed ID: 28155137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
    Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
    Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Houston B; Oosterhuis B; Bjerrum OJ; Rowland M; Garner C
    Eur J Pharm Sci; 2010 May; 40(2):125-31. PubMed ID: 20307657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
    Garner RC
    Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects.
    Zhou XJ; Garner RC; Nicholson S; Kissling CJ; Mayers D
    J Clin Pharmacol; 2009 Dec; 49(12):1408-16. PubMed ID: 19776293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.
    Garner CR; Park KB; French NS; Earnshaw C; Schipani A; Selby AM; Byrne L; Siner S; Crawley FP; Vaes WH; van Duijn E; deLigt R; Varendi H; Lass J; Grynkiewicz G; Maruszak W; Turner MA
    Br J Clin Pharmacol; 2015 Jul; 80(1):157-67. PubMed ID: 25619398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.
    Sarapa N; Hsyu PH; Lappin G; Garner RC
    J Clin Pharmacol; 2005 Oct; 45(10):1198-205. PubMed ID: 16172185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range.
    Sandhu P; Vogel JS; Rose MJ; Ubick EA; Brunner JE; Wallace MA; Adelsberger JK; Baker MP; Henderson PT; Pearson PG; Baillie TA
    Drug Metab Dispos; 2004 Nov; 32(11):1254-9. PubMed ID: 15286054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers.
    Chen L; Mohr SN; Yang CS
    Clin Pharmacol Ther; 1996 Dec; 60(6):651-60. PubMed ID: 8988067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetaminophen plasma level after oral administration in liver cirrhotic patients suffering from schistosomal infection.
    el-Azab G; Youssef MK; Higashi Y; Murakami T; Yata N
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):299-303. PubMed ID: 8832306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations.
    DeGregorio MW; Dingley KH; Wurz GT; Ubick E; Turteltaub KW
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):335-42. PubMed ID: 16047147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An interface for direct analysis of (14)c in nonvolatile samples by accelerator mass spectrometry.
    Liberman RG; Tannenbaum SR; Hughey BJ; Shefer RE; Klinkowstein RE; Prakash C; Harriman SP; Skipper PL
    Anal Chem; 2004 Jan; 76(2):328-34. PubMed ID: 14719879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of high-performance liquid chromatography/chemical reaction interface mass spectrometry for the analysis of conjugated metabolites: a demonstration using deuterated acetaminophen.
    Teffera Y; Abramson F
    Biol Mass Spectrom; 1994 Dec; 23(12):776-83. PubMed ID: 7841212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
    Miyaji Y; Ishizuka T; Kawai K; Hamabe Y; Miyaoka T; Oh-hara T; Ikeda T; Kurihara A
    Drug Metab Pharmacokinet; 2009; 24(2):130-8. PubMed ID: 19430168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.